Almac rewarded for excellence in technology

Monday, April 30, 2012 04:33 PM

Service provider Almac has been recognized for its technological developments, scooping a top award at the recent Belfast Telegraph Northern Ireland Business Awards 2012, in association with British Midland International (BMI).

The pharmaceutical development company collected the Excellence in Technology award, naming it the best of Northern Ireland’s business community across 12 categories.

“Our unique technology is used in a range of applications from medicinal chemistry to the manufacture of specialist chemicals. It has enabled Almac to enter into complementary industries including flavour and fragrances and biofuel arenas,” said Stephen Barr, managing director of Almac’s sciences business unit.

Almac has developed new technology which sets it apart in a difficult chemical market under threat from Asia. Almac’s sciences business unit has set up a dedicated group for discovering and implementing effective processes for biocatalysis—enzymes which effect desired chemical transformations.

Almac is currently collaborating with institutions including Queen’s University Belfast and University College London in a bid to ultimately discover new catalysts with unique properties while providing industrial training opportunities for students and graduates.

 “Companies which adopt and embrace technology as an integral part of their business model tend to be those which drive growth and success. Each of the shortlisted companies in this category has demonstrated excellence in technology in their own way. However, for its use of new technology to fuel its growth and become a world leader in the pharmaceutical and biotechnology sectors, the panel concluded that Almac is this year’s worthy winner,” said Alastair Hamilton, chief executive of Invest NI, and a member of the Belfast Telegraph Business Awards judging panel.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs